Xponance Inc. Increases Position in Envista Holdings Co. (NYSE:NVST)

Xponance Inc. boosted its position in Envista Holdings Co. (NYSE:NVST) by 5.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 19,726 shares of the company’s stock after acquiring an additional 1,077 shares during the period. Xponance Inc.’s holdings in Envista were worth $381,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Royce & Associates LP grew its position in shares of Envista by 88.9% in the fourth quarter. Royce & Associates LP now owns 526,985 shares of the company’s stock valued at $10,166,000 after purchasing an additional 248,081 shares during the period. Natixis Advisors LLC grew its holdings in Envista by 1.8% in the 4th quarter. Natixis Advisors LLC now owns 106,652 shares of the company’s stock valued at $2,057,000 after buying an additional 1,845 shares during the period. Swiss National Bank increased its stake in shares of Envista by 0.8% during the 4th quarter. Swiss National Bank now owns 338,200 shares of the company’s stock valued at $6,524,000 after acquiring an additional 2,800 shares during the last quarter. Pzena Investment Management LLC purchased a new position in shares of Envista during the 4th quarter worth about $16,979,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Envista by 17.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 42,057 shares of the company’s stock worth $811,000 after acquiring an additional 6,320 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NVST. UBS Group cut their price target on shares of Envista from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Monday, March 10th. JPMorgan Chase & Co. cut their target price on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Needham & Company LLC reissued a “hold” rating on shares of Envista in a research report on Thursday, March 6th. Morgan Stanley cut their price objective on Envista from $20.00 to $19.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Finally, Mizuho initiated coverage on shares of Envista in a research report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 target price for the company. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $20.18.

Envista Stock Up 0.5 %

Shares of NYSE NVST opened at $17.55 on Thursday. The firm has a market cap of $3.02 billion, a price-to-earnings ratio of -2.70, a PEG ratio of 1.27 and a beta of 1.33. Envista Holdings Co. has a 1 year low of $15.15 and a 1 year high of $23.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The stock’s 50-day simple moving average is $19.67 and its 200-day simple moving average is $19.59.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. As a group, equities analysts anticipate that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.